BioSig Technologies, Inc. Announces Corporate Rebrand to Streamex Corp.

BioSig Technologies, Inc. Announces Corporate Rebrand to Streamex Corp.

BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig"), which recently merged with Streamex Exchange Corporation ("Streamex") (together, "BSGM" or the "Company"), announced today that it will change its name to Streamex Corp., effective at 12:01 am Eastern Time on Friday, September 12, 2025. In connection with the name change, the Company will change its trading symbol to "STEX." The Company's common stock will commence trading on the Nasdaq Capital Market exchange under the new name and trading symbol on September 12, 2025.

As of September 12, 2025, all Company stock trading, filings, and market related information will be reported under the new symbol "STEX". The Company's CUSIP number will remain unchanged, and no action is required from shareholders. No other aspects of the Company's corporate structure or operations are impacted by the ticker symbol change.

About Streamex Exchange Corporation

Streamex is a Real World Asset ("RWA") tokenization company with Institutional grade infrastructure to bring the gold and commodities market on chain. Enabled by a gold denominated treasury and tokenization technology powering the modern commodities market. Streamex is a wholly owned subsidiary of BioSig Technologies, Inc.

About BioSig Technologies, Inc.

BioSig Technologies, Inc. is a medical device technology company with an advanced digital signal processing technology platform, the PURE EP™ Platform that delivers insights to electrophysiologists for ablation treatments of cardiovascular arrhythmias.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond our control. It is possible that our actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether we will be able to realize the benefits of the acquisition of Streamex, whether shareholder approval of the acquisition will be obtained, and whether we will be able to maintain compliance with Nasdaq's listing criteria in connection with the acquisition and otherwise. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in forward-looking statements, see our filings with the Securities and Exchange Commission, including the section titled "Risk Factors" in our Annual Report on Form 10-K, filed with the SEC on April 15, 2025. We assume no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20250714401245/en/

Investor Relations Contact

Adele Carey
Alliance Advisors Investor Relations
acarey@allianceadvisors.com

Henry McPhie
CEO of BioSig, Co-Founder of Streamex
contact@Streamex.com
https://www.streamex.com/
https://x.com/streamex
Source: BioSig and Streamex


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

BSGM
BioSig Technologies

BioSig Technologies Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
BioSig Technologies

BioSig Technologies

Overview

BioSig Technologies (OTCQB:BSGM) is a medical device company that has developed a proprietary technology platform targeting the rapidly growing electrophysiology (EP) device market. EP devices are used in the treatment of cardiac arrhythmias, which can lead to stroke or even death. The current standard of care is cardiac catheter ablation which has a low efficacy rate.

BioSig Technologies’ goal is to bring to market an advanced biomedical signal processing technology that can address unmet needs for the treatments of challenging and chronic diseases such as arrhythmias. The company is advancing towards commercialization of its PURE EPTM System which is designed to improve the clarity of clinical signals available for EP studies and ablation procedures.

Bringing Next Gen EP Device to Market

Monetary Metals Enters into Exclusive Partnership with Streamex  to Create Tokenized Yield-Bearing Gold Products

Monetary Metals Enters into Exclusive Partnership with Streamex to Create Tokenized Yield-Bearing Gold Products

Monetary Metals has signed an agreement with Streamex to provide yield on physical gold bullion with upwards of $1 billion USD in near term lease capacity

Monetary Metals, the pioneer in gold-and-silver-denominated fixed income products, has partnered with Streamex Exchange Corporation ("Streamex"), which recently merged with BioSig Technologies Inc. (Nasdaq: BSGM). Through this collaboration, Monetary Metals will gain exclusive rights to put Streamex's tokenized gold to work earning yield.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Streamex Exchange Corp NASDAQ-BSGM Creates a Tokenized Yield-Bearing Gold Product Generating up-to 4% through Exclusive Partnership with Monetary Metals

Streamex Exchange Corp NASDAQ-BSGM Creates a Tokenized Yield-Bearing Gold Product Generating up-to 4% through Exclusive Partnership with Monetary Metals

Partnership unlocks exclusive tokenization rights, a four percent (4%) annual yield target on physical bullion, revenue share tied to leasing volumes and the creation of a groundbreaking institutionalized asset providing yield on physical gold holdings

Key Partnership Highlights

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
BioSig Technologies Supplements Clarification on Recent Schedule 14A Filing. Closing of Merger with Streamex Exchange Corporation Not Affected

BioSig Technologies Supplements Clarification on Recent Schedule 14A Filing. Closing of Merger with Streamex Exchange Corporation Not Affected

BioSig Technologies, Inc. ("BioSig" or the "Company"), which recently merged with Streamex Exchange Corporation ("Streamex") (NASDAQ: BSGM), today provided an update regarding the status of the merger and related proxy materials.

The merger transaction closed on May 28, 2025, under the previously executed Share Purchase Agreement. As part of this transaction, 19.99% of BioSig shares are already issuable to Streamex shareholders, with the remaining issuances pending Nasdaq approval.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Streamex  to Participate in the 5th Annual Needham Virtual Crypto 1x1 Conference on September 4th

Streamex to Participate in the 5th Annual Needham Virtual Crypto 1x1 Conference on September 4th

BioSig Technologies, Inc. ("BioSig" or the "Company"), which recently merged with Streamex Exchange Corporation ("Streamex") (NASDAQ: BSGM), a gold tokenization infrastructure company building the foundation for on-chain gold markets, today announced that it will participate in the 5 th annual Needham Virtual Crypto 1x1 Conference on September 4 th 2025. BioSig and Streamex CEO, Henry McPhie and CIO, Mitch Williams will host one on one meetings with institutional investors at the conference.

About Streamex

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer

BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer

BioSig Technologies, Inc. (NASDAQ: BSGM) or ("BioSig" or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of Mr. Ferdinand Groenewald to the position of interim Chief Financial Officer. Personal Bio, Ferdinand Groenewald, age 39 Ferdinand Groenewald is a certified public accountant with significant experience in finance and accounting. He currently serves as Vice President, Finance at Alaunos Therapeutics, Inc. Previously, Mr. Groenewald served as an Independent Outside Director at SYLA Technologies Co., Ltd.; an Independent Director at HeartCore Enterprises, Inc.; an Independent Director at Sushi Ginza Onodera, Inc.; an Accountant at Wrinkle, Gardner & Co. PC; a Senior Staff Accountant at Financial Consulting Strategies LLC; a Controller, VP-Finance & Accounting Officer at Sadot Group, Inc. and a Chief Financial Officer at the same company; and Chief Accounting Officer & VP-Finance at Muscle Maker Development LLC. Mr. Groenewald obtained an undergraduate degree from the University of South Africa.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
BioSig Technologies

BioSig Technologies Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×